SalaryGuide
AboutPricingFor Employers

Marketing jobs

3 marketing jobs

Arrowhead Pharmaceuticals logo
2 months ago

Director, Corporate Communications

Arrowhead Pharmaceuticals

Los Angeles, CA (On-site)Full time$190K/yr – $220K/yr
Arrowhead Pharmaceuticals  logo
2 months ago

Manager, Marketing (HCP KAM)

Arrowhead Pharmaceuticals

Pasadena, CA (On-site)Full time$120K/yr – $145K/yr
Arrowhead Pharmaceuticals  logo
2 months ago

Summer Intern, Marketing Technology

Arrowhead Pharmaceuticals

Pasadena, CA (On-site)Internship

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

3 jobs
Arrowhead Pharmaceuticals logo

Director, Corporate Communications

Arrowhead Pharmaceuticals

Los Angeles, CA (On-site)

$190K/yr - $220K/yrIn-houseFull-timeSenior level10+ years exp.
2 months ago
Arrowhead Pharmaceuticals  logo

Manager, Marketing (HCP KAM)

Arrowhead Pharmaceuticals

Pasadena, CA (On-site)

$120K/yr - $145K/yrIn-houseFull-timeManager5+ years exp.
2 months ago
Arrowhead Pharmaceuticals  logo

Summer Intern, Marketing Technology

Arrowhead Pharmaceuticals

Pasadena, CA (On-site)

In-houseInternshipIntern/new grad1+ years exp.
2 months ago
Arrowhead Pharmaceuticals logo
Arrowhead Pharmaceuticals

Director, Corporate Communications

Los Angeles, CA (On-site)

$190K/yr – $220K/yrSenior Level10+ years expFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own Arrowhead’s external narrative and digital presence, coordinating with IR, Marketing, Medical, and Legal to shape executive messaging, product launches, and high-stakes media opportunities.

  • Strategic planning and storytelling across corporate reputation, website, and social channels.
  • Cross-functional alignment to ensure consistent messaging and brand voice at every touchpoint.
  • Agency oversight to deliver on-brand, high-impact communications programs.

Job Description

Responsibilities

  • Strategic Planning & Execution - Design and deliver comprehensive communication strategies that advance Arrowhead’s corporate reputation and support key initiatives, including the launch of plozasiran and broader pipeline milestones.
  • Corporate and Digital Presence - Lead the strategy, management, and evolution of Arrowhead’s global website and social media platforms to ensure consistent, impactful brand storytelling.
  • Content Development - Craft high-quality written materials—including company narratives, executive communications, press releases, social content, op-eds, and presentations—that align with Arrowhead’s voice and objectives.
  • Agency Oversight - Direct and collaborate with external communications partners to ensure the delivery of high-caliber, on-brand work that drives measurable impact.
  • Cross-Functional Collaboration - Partner closely with Investor Relations, HR, Marketing, Medical, Legal, and other internal teams to align corporate messaging across all touchpoints.
  • Operational Excellence - Support effective budget management and resource allocation for communications programs and agency engagements.

Requirements

  • Bachelor’s degree in Communications, Public Relations, Journalism, Marketing, or a related field
  • 10 years of progressively responsible experience in corporate communications, public relations, or related fields—preferably within the biotechnology, pharmaceutical, or healthcare industry.
  • Proven ability to develop and implement integrated communications strategies that advance corporate reputation and support business goals.
  • Exceptional writing, editing, and storytelling skills with experience crafting content for senior executives, media, and digital channels.
  • Demonstrated success managing media outreach, developing press materials, and preparing leaders for interviews and speaking engagements.
  • Strong understanding of corporate digital strategy, including website management, social media, and content optimization.
  • Ability to effectively partner across departments such as Investor Relations, Marketing, Medical Affairs, and Legal to ensure alignment and compliance.
  • Experience leading teams or agency partners, managing budgets, and delivering results under tight deadlines.
  • Strong understanding of regulatory and compliance considerations in healthcare communications, with sound judgment in sensitive or high-profile situations.
  • Ability to manage multiple projects simultaneously and meet deadlines in a fast-paced environment.
  • You may be required to travel approximately 10 -15%.
  • Candidates must have current, valid authorization to work in the country where this role is located.

Preferred

  • Advanced degree (e.g., MBA, Master’s in Communications, or related field).
  • Experience developing corporate branding, thought leadership, and executive visibility programs.
  • Demonstrated success supporting product launches or scientific communications in the life sciences sector.
  • Background in crisis or issues management, with the ability to counsel senior leaders on reputation-sensitive topics.
  • Familiarity with investor and financial communications, including message alignment between communications and IR functions.
  • Understanding of global communications practices and experience managing multi-market campaigns.
  • Passion for science-driven storytelling and an interest in Arrowhead’s mission to advance RNAi-based therapeutics.

Benefits

  • Arrowhead provides competitive salaries and an excellent benefit package.
Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

3.7 Glassdoor

At Arrowhead Pharmaceuticals we are breaking the mold of medicine. We are pushing the boundaries of therapeutic development and revolutionizing how we care for hard-to-treat illnesses. As a company we harness collaboration and innovation to rapidly advance drugs from discovery to the clinic. All applicants: Please be aware of employment scams using Arrowhead’s name and the names of Arrowhead’s employees. All job related Arrowhead communication should come from the domain @arrowheadpharma.com.

Founded in 1989
Pasadena, California, USA
690 employees
www.arrowheadpharma.com
56% recommend to a friend
91% CEO approval

Traffic Signals

Monthly Visitors
61.8K
Traffic Source Mix
Search
49.2%
Direct
38%
Referral
9.5%
Social
1.9%
Paid
1.3%

Headcount Trend

Current headcount: ~699

Funding

Total Funding
$2.4B
Last Raise
$200M
Post IPO Debt, 2 months ago

Funding History

  • Jan 2026
    Post IPO Equity • $200M
  • Jan 2026
    Post IPO Debt • $625M
  • Nov 2024
    Post IPO Equity • $325M

Recent News

Analyzing Arrowhead Pharmaceuticals After Doubling in Price With RNA Therapy Breakthroughs
Nov 20, 2025 • Yahoo Finance
A Look at Arrowhead Pharmaceuticals’s Valuation Following FDA Approval of First siRNA Therapy for Rare Disease
Nov 20, 2025 • Yahoo Finance
How Analyst Views Are Shifting as Arrowhead Pharmaceuticals Enters a New Phase of Growth
Nov 20, 2025 • Yahoo Finance
With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis
Nov 19, 2025 • MedCity News
US FDA approves Arrowhead's genetic disorder drug
Nov 18, 2025 • Reuters
Arrowhead strikes true with 1st FDA approval, but Ionis competition looms
Nov 18, 2025 • Fierce Pharma
RNAi biotech Arrowhead wins first FDA approval
Nov 18, 2025 • BioPharma Dive
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead (NASDAQ:ARWR)
Nov 17, 2025 • Seeking Alpha
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
Nov 6, 2025 • Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
Nov 4, 2025 • Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 28, 2025 • Business Wire
Is Arrowhead Pharmaceuticals Fairly Priced After Its 90% Year to Date Share Surge in 2025?
Oct 24, 2025 • simplywall.st
How Arrowhead’s Evolving Story Is Shaping Analyst Views and Fair Value Targets
Oct 23, 2025 • Yahoo Finance
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
Oct 21, 2025 • Business Wire
HC Wainwright & Co. Reiterates Arrowhead Pharmaceuticals (ARWR) Buy Recommendation
Oct 8, 2025 • Nasdaq
Arrowhead Pharma stock rating reiterated at Buy by H.C. Wainwright
Oct 8, 2025 • Investing.com
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You
Oct 7, 2025 • simplywall.st
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Oct 7, 2025 • Business Wire
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Oct 7, 2025 • Yahoo Finance
Arrowhead Pharmaceuticals stock hits 52-week high at 34.53 USD
Sep 30, 2025 • Investing.com
6 FDA Decisions to Watch For in Q4
Sep 29, 2025 • BioSpace
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Sep 29, 2025 • Benzinga.com
Novartis Inks Up-to-$5.7B Second Collaboration with Monte Rosa
Sep 16, 2025 • Genetic Engineering News
Arrowhead, Novartis Ink Agreement
Sep 15, 2025 • Los Angeles Business Journal
Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs
Sep 15, 2025 • MedCity News
Ionis, Arrowhead file dueling patent lawsuits over genetic-disorder drug
Sep 11, 2025 • Reuters
Dyslipidemia Market is Anticipated to Accelerate in the Coming 10 Years Due to the Development of New Classes of Drugs, Such as CETP Inhibitors and Gene-based Therapies | DelveInsight
Sep 11, 2025 • PR Newswire UK
Arrowhead files complaint for declaratory judgment against Ionis
Sep 11, 2025 • thefly.com
Arrowhead Pharmaceuticals Sues Ionis Pharmaceuticals Over Plozasiran Patent Dispute
Sep 11, 2025 • MarketScreener
Arrowhead battles Ionis over patent dispute tied to RNAi candidate that could rival Tryngolza
Sep 11, 2025 • FierceBiotech
Dyslipidemia Market is Anticipated to Accelerate in the Coming 10 Years Due to the Development of New Classes of Drugs, Such as CETP Inhibitors and Gene-based Therapies | DelveInsight
Sep 11, 2025 • PR Newswire
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Sep 10, 2025 • BioSpace
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-10-2025 11
Sep 10, 2025 • MarketScreener
Arrowhead Pharmaceuticals, Inc. Requests Regulatory Clearance to Initiate Phase 1/2A Study of Aro-Mapt for the Treatment of Alzheimer's Disease and Other Tauopathies
Sep 10, 2025 • MarketScreener
Arrowhead requests regulatory clearance to initiate ARO-MAPT clinical trial
Sep 10, 2025 • thefly.com
Arrowhead Pharmaceuticals Requests Regulatory Clearance for Tauopathies Phase 1/2a Study
Sep 10, 2025 • MarketScreener
Arrowhead and Novartis Sign Global Licensing Agreement for Preclinical RNA Therapy
Sep 9, 2025 • globallegalchronicle.com
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
Sep 5, 2025 • AOL.com
Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits
Sep 3, 2025 • Yahoo Finance
Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment
Sep 3, 2025 • BioSpace
CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More
Sep 3, 2025 • BioSpace
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 01
Sep 3, 2025 • MarketScreener
Novartis pays $200M for Arrowhead's Parkinson's RNA therapy
Sep 2, 2025 • drugdiscoverytrends.com
Arrowhead Pharmaceuticals Eligible for Up to $2 Billion in Potential Milestone Payments Under New Novartis Deal
Sep 2, 2025 • MarketScreener
Arrowhead, Novartis announce licensing and collaboration agreement for ARO-SNCA
Sep 2, 2025 • thefly.com
Novartis Commits up to $2.2B Toward Developing Arrowhead siRNA Therapy
Sep 2, 2025 • Genetic Engineering News
Novartis Tries Again in Parkinson’s, Putting Up $200M for Arrowhead’s RNAi Therapy
Sep 2, 2025 • MedCity News
Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy
Sep 2, 2025 • MarketScreener
Cytokinetics, Air Lease Corp, Lyft Inc
Sep 2, 2025 • Reuters
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
Sep 2, 2025 • MarketScreener
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
Sep 2, 2025 • BioSpace
Arrowhead, Novartis in up to $2 billion deal for neuromuscular therapy license
Sep 2, 2025 • MarketScreener
Arrowhead jumps on news of $2B deal with Novartis
Sep 2, 2025 • Pharma Letter
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Sep 2, 2025 • BioSpace
Rare Disease Therapeutics Market Projected to Reach US$ 495.27 Billion by 2033, Says DataM Intelligence
Aug 19, 2025 • BioSpace
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Aug 14, 2025 • Investor's Business Daily
Sarepta offloads Arrowhead stake to fund milestone payment
Aug 14, 2025 • Pharma Letter
Sarepta rises on genetic therapy progress
Aug 14, 2025 • Reuters
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
Aug 13, 2025 • Sarepta Therapeutics
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
Aug 13, 2025 • Business Wire
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues
Aug 13, 2025 • BioSpace
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
Aug 13, 2025 • BioSpace
Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment
Aug 13, 2025 • BioSpace
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
Aug 13, 2025 • Business Wire
Sarepta sells $174M in Arrowhead stock to stretch cash runway
Aug 13, 2025 • FierceBiotech
Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor
Aug 12, 2025 • BioSpace
Earnings call transcript: Arrowhead Pharma Q3 2025 misses forecasts
Aug 8, 2025 • Investing.com
Transcript : Arrowhead Pharmaceuticals, Inc., Q3 2025 Earnings Call, Aug 07, 2025
Aug 8, 2025 • MarketScreener
Arrowhead Pharmaceuticals Fiscal Q3 Loss Narrows, Reports Revenue
Aug 8, 2025 • MarketScreener
Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Aug 8, 2025 • Reuters
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript
Aug 7, 2025 • The Motley Fool
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
Aug 7, 2025 • Business Wire
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
Aug 6, 2025 • Business Wire
Sanofi grabs Chinese rights to Arrowhead rare disease drug
Aug 4, 2025 • pharmaphorum
Arrowhead unit sells China rights on plozasiran to Sanofi
Aug 2, 2025 • Pharma Letter
Sanofi acquires China rights to Arrowhead's plozasiran for $395M
Aug 1, 2025 • FirstWord Pharma
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
Aug 1, 2025 • Morningstar.com
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
Aug 1, 2025 • Business Wire
Sanofi pens $395M China pact for Arrowhead metabolic med awaiting approval decision
Aug 1, 2025 • FierceBiotech
Arrowhead Pharmaceuticals Earns $100 Million Milestone Payment From Sarepta
Jul 28, 2025 • MarketScreener
Brown University borrows $500 million more amid ‘deep financial challenges’
Jul 28, 2025 • Boston Globe
Arrowhead says beleaguered Sarepta has 60 days to pay $100M in milestone
Jul 28, 2025 • FierceBiotech
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
Jul 28, 2025 • Business Wire
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
Jul 28, 2025 • Benzinga.com
Arrowhead Shares Bumpy After Partner Troubles
Jul 28, 2025 • Los Angeles Business Journal
Facioscapulohumeral Muscular Dystrophy Pipeline Market Insight Report 2025 | In-depth Analysis of 10+ Companies and 12+ Pipeline Drugs
Jul 28, 2025 • Research and Markets
Sarepta’s Future Increasingly Uncertain as FDA Eyes New Study for Elevidys
Jul 25, 2025 • BioSpace
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - July 24, 2025
Jul 25, 2025 • BioSpace
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
Jul 25, 2025 • Investor's Business Daily
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy
Jul 25, 2025 • Benzinga.com
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 24, 2025 • Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 24, 2025 • MarketScreener
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 24, 2025 • Morningstar.com
Arrowhead Pharmaceuticals, Inc. Issues Statement on Status of its Ongoing Agreement with Sarepta Therapeutics
Jul 23, 2025 • MarketScreener
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
Jul 23, 2025 • MarketScreener
Sarepta's licensing patner Arrowhead expects near-term payments despite setbacks
Jul 23, 2025 • Reuters
Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns
Jul 22, 2025 • Yahoo Finance
Arrowhead Pharmaceuticals Sets Q3 Earnings Date: What Biotech Investors Should Mark on Their Calendar
Jul 21, 2025 • Stock Titan
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Jul 9, 2025 • BioSpace
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
May 12, 2025 • Business Wire